News and Press Releases
T-CURX Announces $20M Series A First Closing Led by BiomedVC to Fund Pipeline of Clinical-Stage CAR-T Programs and Advance Proprietary Non-Viral In Vivo CAR-T Platform
17 December 2025 -- Würzburg, Germany -- T-CURX GmbH (T-CURX) today announces the first closing of a $20M (€ 17.7M) Series A financing with a syndicate of European and Asian investors...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 17, 2025
Innovations- und Gründerzentrum Würzburg Friedrich-Bergius-Ring 15 97076 Würzburg Deutschland/Germany
Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
Enables in vivo delivery of LEU011 harnessing the VivoCell Platform 15 December 2025 -- London, UK and Illinois, US -- Leucid Bio, a privately-held biotechnology company developing innovative Chimeric Antigen Receptor...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 15, 2025
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics
15 December 2025 -- Geneva, Switzerland -- MindMaze Therapeutics Holding SA announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 15, 2025
Gaelic Labs’ acquisition of Athlone boosts Gaelic’s leadership in the Beta Lactam industry
11 December 2025 -- Tipperary, Ireland -- Gaelic Laboratories, a world-class manufacturer of Beta-Lactam (penicillin) products, today announces its acquisition of Athlone Laboratories, a leading developer and manufacturer of oral...
Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: December 11, 2025
Old Waterford Rd, Gurtnafleur, Clonmel, Co. Tipperary, E91 CD92 Ireland
FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
FDA has completed their review of the Neurizon NUZ-001 regimen to the HEALEY ALS Platform Trial Master Protocol This marks the official entry of NUZ-001 as Regimen I in the...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 11, 2025
Level 4, 96-100 Albert Road South Melbourne, VIC 3205 Australia
ProteoNic 2G UNic Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies
11 December 2025 -- Leiden, The Netherlands -- ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology...
Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 11, 2025
Medable Launches Innovation Evidence Workshop – First Collaboration To Bring Leaders Together on DCT Impact, Adoption, and Best Practices
PALO ALTO, California – December 10, 2025 – Medable, the leading provider of AI-powered clinical trial technology, today announced its Innovation Evidence Workshop series, developed in collaboration with and facilitated...
Category:
Posted: December 10, 2025
Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome
Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome The...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2025
661 University Ave, Suite 1300 Toronto, Ontario Canada M5G 0B7
Phillips Medisize Highlights Inhaled Drug Delivery Device Platforms and Scientific Insights at DDL 2025
HUDSON, WI (9 December 2025) Phillips Medisize, a Molex company and a leader in the design, development, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices,...
Category:
Posted: December 9, 2025
Cold Chain Technologies Expands Industry-Leading Reusable Portfolio
Cold Chain Technologies has announced the launch of the EcoFlex 3, an evolution of its shape stable, full-coverage PCM family of EcoFlex reusable shippers. The range, known for its high-performance...
Category:
Posted: December 9, 2025
Astellas To Present New Data on XOSPATA (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML Findings from the Phase 3 MORPHO trial...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 5, 2025
Micro Systems at Drug Delivery to the Lungs Conference 2025
Micro Systems, now part of VANGEST Group, will participate in the DDL Conference, the foremost international event dedicated to pulmonary and nasal drug delivery. VANGEST brings specialised expertise in ultra-precision inhalation...
Category:
Posted: December 5, 2025
Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2025
Evotec-partner Bayer starts Phase 2 study for treatment of patients with Alport syndrome
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndrome Milestone payment to Evotec expected upon first dosing of first study participant in early 2026...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2025
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Groundbreaking myalgic encephalomyelitis study identifies over 250 core genes, shared biology with long COVID, and dozens of drug repurposing opportunities
The study reinforces that ME is a complex multisystemic condition with a clear genetic basis and lays the foundation for future clinical trials that could be faster to recruit and...
Category: BioManufacturing, Clinical Trials, Other, Pharmaceutical
Posted: December 4, 2025
